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Abstract
Purpose—The suitability of fexofenadine as a probe substrate to assess hepatobiliary transport
function in humans was evaluated by pharmacokinetic modeling/simulation and in vitro/in situ
studies using chemical modulators.
Methods—Simulations based on a pharmacokinetic model developed to describe fexofenadine
disposition in humans were conducted to examine the impact of altered hepatobiliary transport on
fexofenadine disposition. The effect of GF120918 on fexofenadine disposition was evaluated in
human sandwich-cultured hepatocytes (SCH). Additionally, the effect of GF120918, bosentan,
and taurocholate on fexofenadine disposition in perfused livers from TR− Wistar rats was
examined.
Results—Based on modeling/simulation, fexofenadine systemic exposure was most sensitive to
changes in the hepatic uptake rate constant, and did not reflect changes in hepatic exposure due to
altered hepatic efflux. GF120918 did not impair fexofenadine biliary excretion in SCH. GF120918
coadministration significantly decreased Cl’biliary to 27.5% of control in perfused livers.
Conclusions—Simulations were in agreement with perfused liver data which predicted changes
in fexofenadine systemic exposure primarily due to altered hepatic uptake. Fexofenadine is not a
suitable probe to assess hepatic efflux function based on systemic concentrations. GF120918-
sensitive protein(s) mediate fexofenadine biliary excretion in rat liver, whereas in human
hepatocytes multiple efflux proteins are involved, in fexofenadine hepatobiliary disposition.
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Introduction
Fexofenadine is an orally administered nonsedating H1-receptor antagonist commonly used
in the treatment of allergic rhinitis and chronic urticaria. The primary elimination pathway
of fexofenadine in humans is biliary excretion of the unchanged species (1). Tahara et al.
demonstrated that biliary clearance accounts for ~56–72% and 40% of total body clearance
in mice and rats, respectively (2). Fexofenadine has a low passive membrane permeability
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with reported Papp values in the absorptive direction of 0.17 × 106 – 0.27 × 106 cm/s
determined in the Caco-2 model (3). Furthermore, the effective jejunal permeability in
healthy human volunteers also was very low: 0.06 × 10−4 ± 0.07 × 10−4 cm/s and 0.04 ×
10−4 ± 0.07 × 10−4 cm/s when fexofenadine was administered alone and with verapamil
using jejunal single-pass perfusion (4,5). Therefore, fexofenadine relies on active hepatic
transport as one of the determinants for systemic clearance.
Identifying the degree and importance of drug-drug interactions in the human liver is very
challenging because the bile and liver compartments are not readily accessible due to the
anatomy of the human hepatobiliary tract. The absolute oral bioavailability of fexofenadine
was reported to be 33% (product information, Hoechst Marion, Roussel, Laval, Quebec,
Canada), with 12% of the total administered dose recovered in urine (1). Therefore, two-
thirds of the bioavailable dose of fexofenadine is presumed to be excreted in bile,
underscoring the importance of this excretory route to overall systemic clearance.
Fexofenadine has been used extensively as an in vivo probe substrate to assess P-
glycoprotein/multidrug resistance protein 1 (P-gp/MDR1) activity; altered systemic
concentrations and overall exposure have been reported due to perturbations in P-gp efflux
in the intestine (6–9). The contribution of P-gp to fexofenadine hepatobiliary transport, or
the degree of interaction with hepatic P-gp, are poorly understood in humans.
The organic anion transporting polypeptides (OATPs), specifically OATP1B1, OATP1B3
and OATP1A2 in humans, and Oatp1a1, Oatp1a4, and Oatp1b2 in rats, have been
implicated in the cellular uptake of fexofenadine (8,10–12). In vitro studies demonstrated
that P-gp mediated the cellular efflux of fexofenadine (10). Thus, fexofenadine has been
recommended as an in vivo probe substrate for P-gp interactions in the intestine (13). In fact
many drug-drug and food-drug interaction studies in humans utilizing fexofenadine as a
probe substrate for P-gp activity have been performed with various co-administered drugs,
herbal supplements and food components (6–9,14–17). Although P-gp plays a role in
limiting intestinal absorption and blood-brain barrier penetration of fexofenadine (2,10),
multiple transport mechanisms play a role in the biliary excretion of fexofenadine (18,19).
In mice fexofenadine is excreted into bile predominantly by multidrug resistance-associated
protein 2 (Mrp2), and to a minor extent by P-gp and other yet unidentified mechanisms (18).
The mechanisms of biliary excretion of fexofenadine in rats and humans have not been
elucidated. However, the biliary excretion rate and intrinsic biliary clearance of
fexofenadine in naturally occurring Mrp2-deficient TR− and Eisai hyperbilirubinemic
(EHBR) rats were unchanged compared to wild-type rats (2,18). In the present studies, the
role of other canalicular transport proteins including the bile salt export pump (Bsep) and P-
gp in fexofenadine biliary clearance was investigated in rat perfused livers.
Bsep is primarily involved in the biliary excretion of bile acids (20), but also is capable of
transporting some xenobiotics including vinblastine, pravastatin and fexofenadine in
transfected expression systems (19,21,22). P-gp serves an important barrier function and is
responsible for biliary excretion of bulky hydrophobic and cationic substrates, including
many chemotherapeutics agents, cardiac glycosides, cyclosporin A, HIV protease inhibitors,
and fexofenadine, as mentioned above (23). Bcrp transports sulfated steroids and many
anticancer agents in addition to some organic anions and cations (24–26). Fexofenadine does
not appear to be a BCRP/Bcrp substrate based on the results of studies utilizing Bcrp
knockout mice and MDCKII cells transfected with human BCRP (2,19).
The objective of the present study was to examine the suitability of fexofenadine as a probe
substrate for altered hepatobiliary transport in humans. A pharmacokinetic model was
developed to describe the disposition of fexofenadine in healthy human subjects, and
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simulations were conducted to examine the effect of inhibition or induction of hepatic
transport processes on fexofenadine disposition. The findings from compartmental modeling
and simulation were tested using chemical modulators of hepatic transport proteins. The
effect of GF120918, a human P-gp and BCRP inhibitor, was assessed in human sandwich-
cultured hepatocytes (SCH). In addition, livers from Mrp2-deficient TR− rats were perfused
in situ in a single-pass manner in the presence and absence of the Bsep inhibitor bosentan
(27), and GF120918 to examine the impact of modulation of uptake and efflux proteins on
fexofendadine hepatobiliary disposition. Furthermore, the taurocholate infusion in perfused
livers was withheld to perturb trafficking of ATP-binding cassette (ABC) transport proteins
to the canalicular membrane (28,29) in order to assess the contribution of impaired biliary
excretion to fexofenadine disposition.
Material and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), insulin, MEM non-essential amino acids
solution (100x), L-glutamine, insulin and penicillin G-streptomycin solution were purchased
from Invitrogen (Carlsbad, CA). Collagenase (type 4), fetal bovine serum (FBS),
fexofenadine, cetirizine, sodium taurocholate, digoxin, Triton X-100, dexamethasone,
methanol, Krebs-Henseleit buffer packs (K-3753) and Hanks’ balanced salt solution (HBSS)
modified with (H-1387) or without (H-4891) calcium chloride were obtained from Sigma-
Aldrich (St. Louis, MO). BioCoat™ collagen I plates, Matrigel™ basement membrane
matrix, and ITS+™ (insulin/transferrin/selenium) culture supplement were purchased from
BD Biosciences Discovery Labware (Bedford, MA). [3H]-taurocholate (5 Ci/mmol, >97%
purity) and [3H]-digoxin (40 Ci/mmol, >97% purity) were obtained from PerkinElmer Life
and Analytical Sciences (Boston, MA). Bio-Safe II™ liquid scintillation cocktail was
obtained from Research Products International (Mt. Prospect, IL). Centrifree®
micropartition devices were obtained from Millipore (Billerica, MA). Bicinchoninic acid
(BCA) protein assay reagents and BSA for the protein assay standard were purchased from
Pierce Chemical Co. (Rockford, IL). N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-
isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide
(GF120918) was a gift from GlaxoSmithKline (Research Triangle Park, NC). All other
chemicals and reagents were of analytical grade and available from commercial sources.
Pharmacokinetic Modeling
Mean fexofenadine plasma concentrations and urinary excretion rate data were estimated
from previously published data in healthy human subjects after a single oral dose of 120 mg
(9). Cumulative mass in bile after 48 hours was estimated based on the assumption that
bioavailability of oral fexofenadine was 33% (product information, Hoechst Marion,
Roussel, Laval, Quebec, Canada), of which approximately one-third of the 120 mg dose was
excreted into urine (30), and two-thirds was excreted into bile. To achieve model parsimony,
bioavailability of fexofendine was fixed at the aforementioned literature value (33%). The
adoption of fixed bioavailability accounted for the first pass extraction of fexofenadine and
the remaining fixed fraction of dose was absorbed directly into the systemic compartment.
This is supported by the fact that fexofenadine has a low hepatic uptake clearance. A
number of different compartmental models were developed (including a peripheral
compartment in addition to the liver compartment, with elimination from the peripheral,
central and/or liver compartments) using the concentration- and mass-time profiles.
Differential equations describing the disposition of fexofenadine in the compartments were
fit simultaneously to plasma, urine and bile profiles using nonlinear least-squares regression
(WinNonlin v. 4.1 Pharsight Corporation, Mountain View, CA). Different initial parameter
values were used in the fitting process along with broad lower and upper bounds to have
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confidence in the final parameter estimates and avoid convergence at a local minimum. The
goodness of fit was based on Akaike’s Information Criterion, the residual sum of squares,
coefficients of variation on the parameter estimates, the condition number, and visual
inspection of the residual plots and of model fitting to the concentration- and mass-time
profiles. Due to the disparity in the number of data points for the mass in bile and the urinary
excretion rate data compared with the plasma concentration data, a weighting scheme was
used to account for the relative contribution of each data set to the overall number of data
points. Each data point was assigned a weight of,  where n is the fraction of the
total number of data points that support a particular sample matrix. The optimal model that
best described the data is shown in Figure I. This model included a compartment depicting
the systemic circulation described by the plasma concentration-time profile after absorption,
represented by a first-order rate constant Kabsorb, from the gut compartment. A first-order
rate constant, K12, governed fexofenadine uptake from the central compartment into a
peripheral compartment, representing the liver. K21 represented a first-order rate constant
for hepatic basolateral efflux; Kbile and Kurine represented biliary and urinary excretion rate
constants, respectively. The following differential equations described fexofenadine
disposition in healthy human subjects:
Pharmacokinetic Simulations
The contribution of each parameter in this compartment model to the overall disposition of
fexofenadine was assessed through a series of simulation experiments. Each parameter was
varied sequentially from the baseline value by either increasing (i.e. induction) or decreasing
(i.e. inhibition) the parameter estimate by 50%, 100% or 300%. The concentration-, mass-
and excretion rate-time profiles were simulated using WinNonlin v.4.1, and the area under
the curve (AUC) for the plasma concentration-time and hepatic mass-time profiles were
calculated utilizing a standard noncompartmental approach.
Isolation and In Vitro Culture of Primary Human Hepatocytes
Human liver tissue was obtained by qualified medical staff from the University of North
Carolina, School of Medicine, as waste from surgical resection. Written informed consent
was obtained from patients before undergoing hepatic surgery. IRB approval was obtained
for the collection of human liver tissue. Hepatocytes were isolated by a modification of the
two-step collagenase perfusion, as described previously (31). Cell viability, determined by
trypan blue exclusion, was >88%. Hepatocytes were seeded (~1.5 × 106 cells/well) in 6-well
BioCoat™ plates in DMEM without phenol red supplemented with 2 mM L-glutamine, 1%
(v/v) MEM non-essential amino acids, 100 units penicillin G sodium, 100 µg streptomycin
sulfate, 1 µM dexamethasone, 5% (v/v) FBS, and 10 µM insulin (day 0 of culture), and
allowed to attach for 2–6 h in a humidified incubator (95% O2, 5% CO2) at 37°C. After cell
attachment, culture plates were swirled gently and the culture medium was replaced with the
same medium. Cells were overlaid 16–24 h (day 1 of culture) after seeding with ice-cold
Matrigel™ basement membrane matrix (0.25 mg/mL) in 2 mL/well cold serum-free DMEM
containing 2 mM L-glutamine, 1% (v/v) MEM non-essential amino acids, 100 units
penicillin G sodium, 100 µg streptomycin sulfate, 0.1 µM dexamethasone, and 1% (v/v) ITS
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+™. The culture medium was changed every 24 h until experiments were performed on day
9–10 of culture.
Accumulation Experiments
The method to determine substrate accumulation in SCH has been described previously (32).
Briefly, hepatocytes were rinsed twice with 2 mL warm HBSS containing Ca2+ (standard
buffer) or Ca2+-free HBSS and incubated with 2 mL of the same buffer for 10 min at 37°C
(to maintain tight junction integrity and bile canalicular networks, or disrupt tight junctions
and open bile canalicular networks, respectively). The buffer was removed, and the cells
were incubated for 10 min at 37°C with 1.5 mL of [3H]-taurocholate (1 µM), [3H]-digoxin
(1 µM) in the presence and absence of 2 µM GF120918, or for 30 min with fexofenadine (5
µM) in the presence and absence of 2 µM GF120918 in standard buffer. Hepatocytes were
rinsed vigorously three times with 2 mL ice-cold standard buffer following the incubation.
Taurocholate- and digoxin-treated hepatocytes were lysed with 1 mL 0.5% (v/v) Triton
X-100 in phosphate-buffered saline by placing plates on an orbital shaker for a minimum of
20 min at room temperature. Substrate uptake was corrected for nonspecific binding by
subtracting uptake on blank six-well Biocoat™ plates overlaid with Matrigel™. Data were
normalized to protein concentration in each well, determined in duplicate aliquots using
BCA protein assay reagent kit (Pierce) as instructed by the manufacturer. BSA, as supplied
by the manufacturer, was used as a standard (0.2 – 1 mg/mL). Due to incompatability of the
protein assay with methanol, the average protein concentration for standard HBSS or Ca2+-
free HBSS incubations in the same liver preparation was used to normalize fexofenadine
content. The [3H]-taurocholate and [3H]-digoxin samples were analyzed by liquid
scintillation spectroscopy in a Packard Tri-Carb scintillation counter (PerkinElmer Life and
Analytical Sciences). Fexofenadine-treated hepatocytes were lysed with 1 mL 70% (v/v)
ice-cold methanol/water and stored at −80°C until analysis. The cells were scraped off the
plates and centrifuged at 10,000 g for 5 min before analysis by LC/MS/MS.
Animals
Male Mrp2-deficient TR− rats bred at the University of North Carolina (212–341 g;
breeding stock obtained from Dr. Mary Vore, University of Kentucky, Lexington, KY) were
used for perfused liver studies. Rats had free access to water and food prior to surgery. All
animal procedures complied with the guidelines of the Institutional Animal Care and Use
Committee (University of North Carolina, Chapel Hill, NC).
In Situ Liver Perfusion
All experimental procedures were performed under full anesthesia induced with ketamine/
xylazine (140/8 mg/kg i.p.). The liver perfusion procedure was modified slightly from the
previous report of Tian et al (2008). Briefly, the common bile duct was cannulated with
polyethylene PE-10 tubing (Becton Dickinson, Parsippany, NJ). The portal vein was
cannulated with a 16-gauge catheter (B. Braun Medical Inc., Bethlehem, PA), the abdominal
vena cava below the liver was severed immediately by incision, and the inferior vena cava
above the liver was cannulated with a 14-gauge catheter. Subsequently, the inferior vena
cava was ligated between the liver and kidney to direct all perfusate outflow through the
cannulated inferior vena cava above the liver. The liver was perfused in a single-pass
manner (30 ml/min with fexofenadine-free, continually oxygenated, Krebs-Henseleit buffer
in the presence of 5 µM taurocholate, unless otherwise indicated) for an equilibration period
of ~15 min. Following the pre-perfusion period to allow for equilibration of temperature
(37°C) and bile flow, the liver was perfused for 60 min with buffer containing 5 µM
taurocholate, unless otherwise indicated, and 0.5 µM fexofenadine alone, or with 2 µM
GF120918 or 5 µM bosentan. Bile and outflow perfusate were collected in 10-min intervals
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in toto, and livers were isolated at the end of perfusion and stored at −80°C until analysis.
Perfusion pressure and bile flow were used to assess liver viability (33).
Determination of Protein Binding
Livers were thawed and homogenenized in three volumes (v/w) of 0.1 M phosphate buffer
(pH 7.4). Liver homogenate samples (500 µL) were placed in Centrifree® micropartition
devices and centrifuged at 1000 g at 4°C for 10 min to pass ~10% of the original volume
through the filter. The absence-of-protein condition was used to assess non-specific binding.
Samples were obtained from above (total concentration in the presence of protein) and
below (unbound concentration) the filter, and analyzed by liquid chromatography with
detection by tandem mass spectrometry (LC/MS/MS).
Analytical Methods
Bile, outflow perfusate, liver homogenate, ultracentrifugation filtrate and human SCH
lysates were analyzed by LC/MS/MS (Applied Biosystems API 4000 triple quadrupole with
TurboIonSpray interface, MDS Sciex, Concord, ON, Canada). Fexofenadine and cetirizine
(internal standard) were eluted from an Aquasil C18 column (5µm, 50mm × 2.1mm,
Thermo-Electron, Waltham, MA) using a mobile phase gradient at a flow rate of 0.75 mL/
min (A: 0.1% formic acid in water, B: 0.1% formic acid in methanol); 0–0.8 min hold at
10% B, 0.8–3.5 min linear increase to 85% B, 3.5–4.0 min hold at 85% B, 4.0–4.5 min
return to 10% B, 4.5–5 min hold at 10% B (Shimazdu solvent delivery system, Columbia,
MD). Fexofenadine and the internal standard, cetirizine, were detected in positive ion mode
using multiple reaction monitoring: fexofenadine, 502.3 → 466.4 m/z; cetirizine, 389.0 →
201.0 m/z. Fexofenadine was quantified with seven point standard curves prepared in the
appropriate matrix, and coefficients of variation were <14%.
Data Analysis
For SCH studies, the biliary excretion index (BEI, %) and in vitro biliary clearance (Clbiliary,
mL/min/kg) were calculated using B-CLEAR® technology [Qualyst, Inc., Raleigh, NC;
(32)]:
(1)
where substrate accumulation in the cell + bile compartments was determined in hepatocytes
preincubated in standard buffer; cellular accumulation of substrate was determined in
hepatocytes preincubated with Ca2+-free HBSS.
(2)
where AUC0-T represents the product of the incubation time (T) and the initial concentration
in the medium. In vitro Clbiliary values were scaled per kilogram body weight using 1 mg
protein/1.5 × 106 cells (the typical value obtained in all preparations), 107 × 106
hepatocytes/g of human liver tissue (34), and 25.7 g of liver tissue per kg of body weight
(35).
Steady-state fexofenadine concentrations were defined as the average perfusate
concentration during the 50- to 60-min interval based on experiments performed by (18) in
which outflow fexofenadine concentrations reached a plateau after 50 min of infusion in in
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situ single-pass perfused rat liver studies. The hepatic extraction ratio was calculated as the
ratio of the difference between steady-state inflow and outflow fexofenadine concentrations
and the steady-state inflow concentration. Unbound intrinsic biliary clearance (Cl’biliary) was
calculated as the ratio of the fexofenadine biliary excretion rate and the unbound liver
concentration (Cliver,unbound).
All data were reported as mean ± SD (n = 3–4 per group). Statistical significance was
assessed by one-way analysis of variance (ANOVA) with Dunnett’s post-hoc test. In all
cases, p < 0.05 was considered to be statistically significant.
Results
Pharmacokinetic Modeling and Simulation of Data from Healthy Human Subjects
The model scheme depicted in Fig. I best described the fexofenadine plasma concentration
vs. time and urinary excretion rate vs. time obtained from previously published data (9), as
shown in Fig. II. Parameter estimates for fexofenadine disposition based on the human data
are reported in Table I. The ratio of the biliary (Kbile) and basolateral (K21) efflux rate
constants was 5.6, suggesting that once in the liver, the predominant process that determines
fexofenadine disposition is excretion into bile.
To assess the influence of alterations in hepatic uptake (K12) or excretion (K21, Kbile) on
fexofenadine systemic and hepatic exposure, simulations were performed using the
parameter estimates in Table I. Based on these simulations, a 50%, 100% and 300% change
in the hepatic uptake rate constant (K12) resulted in a 18% or greater difference in the
systemic exposure of fexofenadine, determined as the AUC of the plasma concentration-
time profile (Fig. III.A). Similar changes in the basolateral efflux rate constant (K21), and
biliary excretion rate constant (Kbile), resulted in less than a 7% change in the systemic
AUC, except for the 300% increase in basolateral efflux, which increased the systemic AUC
~14%. Importantly, hepatic exposure, determined as the AUC of the hepatic mass-time
profile, was sensitive to changes in the hepatic uptake rate constant (K12) as well as the
biliary excretion rate constant (Kbile). A 50%, 100% and 300% change in K12 resulted in a
12–16%, 26–30% and 39–46% change, respectively in hepatic exposure. In contrast to
systemic exposure, perturbations in Kbile produced at least a 18% difference in hepatic
exposure for all simulations. Alterations in the basolateral efflux rate constant (K21) resulted
in negligible changes in hepatic exposure of fexofenadine.
Biliary Excretion of Fexofenadine in Human Sandwich-Cultured Hepatocytes
The in vitro biliary excretion of [3H]taurocholate, [3H]digoxin and fexofenadine was
measured in human SCH from two unrelated donors. Cellular accumulation of the model
bile acid [3H]taurocholate (73.8 and 57.8 pmol/mg protein) and BEI [58.1 and 52.4 %,
(Table II)] were consistent with previous data generated in this model system. As a positive
control, the P-gp substrate [3H]digoxin was evaluated in the presence and absence of
GF120918. Cellular accumulation of [3H]digoxin was increased slightly by GF120918 for
one liver (21.0 vs. 29.9 pmol/mg protein); the BEI and in vitro biliary clearance of
[3H]digoxin were abolished completely by GF120918 in both livers (Table II). Fexofenadine
cellular accumulation increased slightly in the presence of GF120918 (66.2 vs. 93.2 and 62.5
vs. 65.1 pmol/mg protein), but fexofenadine BEI and in vitro biliary clearance were not
affected by GF120918 in human SCH. Both, BEI and in vitro biliary clearance values were
decreased in the second liver donor compared to the first for all three compounds,
suggesting decreased development of the bile canalicular networks and/or canalicular
protein function in hepatocytes from this liver donor.
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Fexofenadine Recovery in Perfused Livers from TR− Rats
Bile flow rates (mean ± SD) in TR− rat livers perfused with 5 µM taurocholate and 0.5 µM
fexofenadine (control) or in combination with either 2 µM GF120918 or 5 µM bosentan,
were 0.54 ± 0.04, 0.52 ± 0.02 and 0.60 ± 0.05 µL/min/g liver, respectively. Compared to
control values, bile flow rates in livers from TR− rats perfused without 5 µM taurocholate
were decreased ~50% to 0.28 ± 0.03 µL/min/g liver. Bile flow in each group was stable
during the 60-min perfusion period (Fig. IV.A). The total recovery of fexofenadine at the
end of the perfusion period, as a percentage of the total infused dose, was 86 ± 16% in
control, 77 ± 9% without taurocholate, 75 ± 4% with GF120918, and 81 ± 9% with
bosentan.
Fexofenadine concentrations in outflow perfusate are presented in Fig. IV.B (mean ± SD).
Outflow perfusate concentrations at the end of the infusion were significantly increased in
the presence of GF120918 (171.5 ± 58.8 pmol/mL) and bosentan (209.0 ± 19.4 pmol/mL),
compared to control (92.3 ± 29.4 pmol/mL); GF120918 and bosentan significantly
decreased the extraction ratio of fexofenadine (Fig. IV.B; Table III)]. The biliary excretion
rate of fexofenadine was decreased ~38% when taurocholate was withheld from the inflow
perfusate; coadministration of GF120918 and bosentan decreased the fexofenadine biliary
excretion rate ~75% and ~35%, respectively (Fig. IV.C; Table III). Unbound fexofenadine
concentrations in livers were not significantly different among the treatment groups,
although unbound liver concentrations tended to be higher in the presence of GF120918.
Bosentan significantly decreased the ratio of fexofenadine unbound liver concentrations to
outflow perfusate concentrations, consistent with inhibition of fexofenadine partitioning
from perfusate to liver. Fexofenadine Clbiliary was only significantly decreased in the
presence of GF120918.
Discussion
To evaluate the utility of fexofenadine as a probe substrate for hepatobiliary transport
function,, pharmacokinetic modeling and simulation studies based on previously published
data were utilized to examine the impact of hepatic transport modulation on the systemic
and hepatic exposure of fexofenadine in humans. Furthermore, modeling and simulation of
fexofenadine data in humans was supported by in vitro studies in human SCH and perfused
rat livers using various chemical modulators of hepatic transport proteins.
The pharmacokinetic model adequately described the mean fexofenadine plasma
concentrations, urinary excretion rate and estimated cumulative mass in bile data after a 120
mg oral dose (Fig II); low variability was associated with the parameter estimates (Table I).
The predominant process determining the systemic clearance of fexofenadine in humans
appears to be hepatic uptake when comparing the rate constants (Table I) governing
disposition of fexofenadine in humans. Although, this is a very low clearance process when
comparing the product of K12 (hepatic uptake) and Vc which is 6.92 L/h with hepatic blood
flow in humans ~87 L/h (35).
To examine the sensitivity of systemic and hepatic exposure to changes in hepatic uptake
and efflux processes in humans, a simulation approach was utilized, and the rate constants
representing the active transport processes governing hepatic uptake and efflux were
modulated in a systematic manner. The results indicated that the central compartment,
representing the systemic circulation, is most sensitive to changes in the hepatic uptake rate
constant, rather than the basolateral efflux rate constant, or the biliary excretion rate constant
(Fig. III). This finding is supported by the absence of drug-drug interactions (defined as a
significant change in fexofenadine pharmacokinetics) when fexofenadine is administered
with known P-gp modulators such as diltiazem (9) or verapamil (5), or in individuals with P-
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gp polymorphisms (C3435T and G2677T) (14,36,37). Furthermore, simulations are
consistent with drug-drug interaction studies with known OATP modulators such as fruit
juices (30), and in individuals with polymorphisms of the SLCO1B1 gene (38), where
significant changes in fexofenadine AUC have been reported. In contrast, simulations
revealed that hepatic fexofenadine exposure in humans was sensitive to alterations in either
the hepatic uptake rate constant or the biliary excretion rate constant. Most importantly, the
marked increase in fexofenadine hepatic exposure due to modulation of Kbile was not
reflected by changes in the systemic concentration-time profile in humans (Fig. III). This
demonstrates the difficulty in assessing hepatic exposure by only measuring systemic
concentrations of a substrate like fexofenadine. In humans, multiple transport proteins
appear to be involved in fexofenadine biliary excretion, thus, the suitability of this substrate
as a probe to assess altered hepatic excretion in humans is limited. However, based on
perfused rat liver data, the GF120918-sensitive component of biliary excretion plays a
predominant role in canalicular transport in rats; inhibition of fexofenadine biliary excretion
resulted in increased perfusate concentrations. These data underscore the importance of
species differences in hepatobiliary drug transport, and the important role that compensatory
transport proteins may play in determining the systemic and/or hepatic exposure of a
substrate when hepatic transport processes are modulated. Furthermore, as depicted in
Figure III, significant interactions in hepatic excretion of a drug that displays hepatobiliary
disposition characteristics similar to fexofenadine may not be reflected by changes in the
plasma concentration-time profile.
To investigate the changes in systemic and hepatic exposure after inhibition of fexofenadine
biliary excretion, and examine the involvement of P-gp in the biliary excretion of
fexofenadine in humans, studies were performed in human SCH using the inhibitor
GF120918. The possible involvement of BCRP was ruled out based on previously published
data generated in MDCKII cells transfected with human BCRP demonstrating that BCRP
does not transport fexofenadine (19). OATP and P-gp function were assessed by the probe
substrate [3H]digoxin as a positive control. Intracellular accumulation and BEI values of
[3H]digoxin were comparable to previously reported data (39,40). GF120918 (2 µM), used
previously to inhibit P-gp in rat SCH (39), completely abolished the BEI and in vitro Clbiliary
of [3H]digoxin in human SCH (Table II). Fexofenadine exhibited a low BEI and in vitro
Clbiliary which was marginally affected by GF120918. The trend towards increased
hepatocellular accumulation of fexofenadine in the presence of GF120918 (Table II) is in
agreement with the pharmacokinetic simulations which predicted that hepatic accumulation
would increase when the biliary excretion rate constant was decreased (Fig III.B). However
the possibility that GF120918-mediated inhibition of basolateral efflux results in increased
hepatocellular accumulation of fexofenadine cannot be ruled out. These data suggest that
GF120918-sensitive protein(s) (presumably P-gp) play a minor role in fexofenadine biliary
excretion in human hepatocytes. Quite possibly, other canalicular transport proteins fully
compensate when GF120918-sensitive protein(s) is/are inhibited. Fexofenadine is a known
substrate for human MRP2 and BSEP based on previously published studies using MDCKII
and HEK293 transfected cells (11,19). These data imply that fexofenadine would not be a
suitable probe substrate in humans to assess altered biliary excretion associated with a
specific canalicular transport process.
Due to the limited availability of human hepatocytes, the lack of specific MRP2 inhibitors
that would not affect OATP-mediated fexofenadine uptake, and the multiplicity of efflux
transport proteins involved in fexofenadine hepatobiliary disposition in humans (19,41),
further investigations were conducted in rat perfused livers. Previous studies demonstrated
that the biliary excretion and intrinsic biliary clearance of fexofenadine were not
significantly different in wild-type and Mrp2-deficient rats (2,18). Therefore, TR− rats were
employed in the present studies to rule out any compensatory role of Mrp2 in the biliary
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excretion of fexofenadine. Co-infusion of fexofenadine and GF120918 resulted in a
significant decrease in both the biliary excretion rate and the intrinsic biliary clearance of
fexofenadine (Fig. IV.C;Table III). Fexofenadine is a substrate of the basolateral efflux
protein Mrp3 (19,41), which is upregulated 7-fold in TR− rats (42) and may explain the
significant increase in outflow perfusate concentrations of fexofenadine in the presence of
GF120918. This observation is supported by simulations examining the impact of induction
of the basolateral efflux rate constant (K21) on fexofenadine disposition, which resulted in
noticeable changes in the plasma AUC (Fig III.A). Although fexofenadine liver
concentrations tended to be higher when biliary excretion was inhibited by GF120918 in
perfused TR− rat livers, as predicted in humans based on the pharmacokinetic simulations,
differences failed to reach statistical significance. This apparent discrepancy could be due to
species differences in the role of basolateral efflux proteins as a determinant of fexofenadine
hepatobiliary disposition. In humans perturbations in biliary excretion only affected hepatic
exposure; basolateral efflux was such a minor pathway that systemic exposure was not
influenced by such perturbations. Basolateral efflux may play a more important role in
systemic exposure in the rat based on this data, and also the mouse as reported previously
using Mrp2 knock-out mice (19,41).
Fexofenadine is not a substrate of human or mouse BCRP/Bcrp based on previously
published data generated in MDCKII cells transfected with human BCRP, or in Bcrp
knockout mice (2,19). Therefore, the predominant pathway for excretion of fexofenadine
into rat bile is likely P-gp, in contrast to the mouse in which Mrp2 plays the greatest role
(18). This is supported by Milne et al., who demonstrated that the P-gp inhibitor
erythromycin decreased cumulative recovery of fexofenadine in bile, and slightly increased
hepatic accumulation and the perfusate AUC of fexofenadine in rat isolated perfused livers
(43). Interestingly, mass balance data reported by these investigators indicated that 50% of
the fexofenadine dose remained in the liver at the end of perfusion. Our studies revealed that
~40% of the fexofenadine dose was retained within the rat liver at the end of perfusion. As
previously suggested, the liver may act as a reversible binding or sequestration site as well
as an elimination organ for fexofenadine (5).
Withholding taurocholate from the perfusion buffer resulted in a significant decrease in the
biliary excretion rate of fexofenadine (Fig. IV.C; Table III). Hepatic fexofenadine
concentrations were similar to control livers perfused with fexofenadine and taurocholate.
The significant decrease in the biliary excretion of fexofenadine may be due to reduced
canalicular localization of Bsep and other ATP binding cassette (ABC) transport proteins
that mediate fexofenadine biliary excretion, causing a modest shift in the route of
fexofenadine excretion to perfusate. Treatment of rats in vivo with taurocholate has been
shown to modestly increase canalicular ABC transport protein expression on the hepatocyte
canalicular membrane within minutes (28, 29).
Fexofenadine has been shown to be a substrate of human and rat BSEP/Bsep using in vitro
transfected systems (19). Therefore, bosentan, a known inhibitor of Bsep (27), was
concurrently infused into the perfusate. Although bosentan was expected to decrease
fexofenadine biliary excretion, only a 35% decrease in the biliary excretion rate was noted
(Table III). Interestingly, bosentan significantly decreased the extraction ratio and
partitioning of fexofenadine from perfusate to liver (Table III). These results may be due to
bosentan-mediated inhibition of fexofenadine hepatic uptake, and/or to increased basolateral
efflux as a result of inhibition of fexofenadine biliary excretion; either scenario would result
in significantly increased fexofenadine perfusate concentrations (Fig. IV.B;Table III).
Bosentan is a substrate of all three Oatp isoforms in the rat liver [Oatp1a1, 1a4 and 1b2;
(44)] which are responsible for fexofenadine hepatic uptake (8). Furthermore, bosentan (100
µM) competitively inhibited (by ~40%) the transport of model probes of the human
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OATP1B1, 1B3 and 2B1 isoforms in transfected CHO cell lines (45). Interestingly, the
simulations of impaired hepatic uptake of fexofenadine in humans agreed with the results
from perfused rat liver studies: perfusate (a surrogate for plasma) concentrations
significantly increased in the presence of bosentan (Fig. IV.B).
Conclusion
In summary, pharmacokinetic modeling and simulation studies revealed that fexofenadine in
humans is not an optimal probe for any specific hepatic efflux transport protein due to
compensatory hepatic transport mechanisms. Systemic fexofenadine concentrations are most
sensitive to changes in fexofenadine hepatic uptake. Increased or decreased hepatocyte
concentrations as a result of impaired or induced biliary or hepatic basolateral efflux,
respectively, associated with drug-drug interactions or genetic mutations, has minimal
impact on systemic exposure. Furthermore, pharmacokinetic modeling and simulation
studies were in good agreement with preclinical data that predicted changes in systemic and
liver exposure due to inhibition of hepatic uptake. Studies in perfused livers from TR− rats
demonstrated that fexofenadine biliary excretion is mediated primarily by a GF120918-
sensitive (presumably P-gp) mechanism. In contrast, either P-gp plays a minor role in
fexofenadine biliary excretion in human hepatocytes, or other canalicular transport proteins
fully compensate when P-gp is inhibited.
List of Nonstandard Abbreviations
SCH sandwich-cultured hepatocytes
OATP organic anion transporting polypeptide
MDR1 multidrug resistance protein 1
P-gp P-glycoprotein
Mrp multidrug resistance-associated protein
TR− Mrp2-deficient Wistar rat
EHBR Eisai hyperbilirubinemic rats
Bsep bile salt export pump
Bcrp breast cancer resistance protein




DMEM Dulbecco’s modified Eagle’s medium
FBS Fetal bovine serum
HBSS Hanks’ balanced salt solution
BCA Bicinchoninic acid
LC/MS/MS liquid chromatography with detection by tandem mass spectrometry
AUC area under the curve
ABC ATP binding cassette
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Model scheme depicting fexofenadine disposition in healthy humans. Xgut represents the
amount of fexofenadine in the gut after an oral dose; Kabsorb represents the first–order
absorption rate constant; CC represents the concentration of fexofenadine in the central
compartment (systemic circulation) with volume VC; K12 represents the first–order rate
constant for hepatic uptake; K21 represents the first-order rate constant for hepatic
basolateral efflux; Xliver represents the amount of fexofenadine in the liver; Kbile represents
the first–order rate constant for biliary excretion; Xbile represents the amount of
fexofenadine in bile; Kurine represents the first–order rate constant for urinary excretion;
Xurine represents the amount of fexofenadine in urine.
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Mean fexofenadine disposition in healthy humans. The curves represent the best fit of the
pharmacokinetic model based on the scheme depicted in Fig. I to the data obtained from
Shimizu et al. (9). The plasma concentration-time profile (♦ solid line) and urinary excretion
rate-time profile (▲ dashed line) are plotted on log-linear scale. Symbols represent actual
data points while lines represent the best fit of the model to the data.
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Simulated percentage change from baseline in the AUC of the (A) plasma concentration-
time profile, predictive of systemic exposure, and (B) hepatic mass-time profile, predictive
of hepatic exposure, associated with perturbations in the hepatic uptake rate constant (K12;
solid bars), basolateral efflux rate constant (K21; hatched bars) and biliary excretion rate
constant (Kbile; open bars).
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Data generated in perfused livers from Mrp2-deficient TR− rats. (A) Bile flow rates, (B)
Fexofenadine concentrations in outflow perfusate, and (C) Biliary excretion rates of
fexofenadine in livers perfused with 0.5 µM fexofenadine (●), 0.5 µM fexofenadine without
5 µM taurocholate (□), 0.5 µM fexofenadine + GF120918 (△), and 0.5 µM fexofenadine +
bosentan (◊). Perfusate buffer contained 5 µM taurocholate, unless otherwise noted. Data
represent mean ± SD (n-3–4 per group).
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Table I
Pharmacokinetic parameters governing fexofenadine disposition in healthy humans estimated using nonlinear
regression analysis based on the compartmental model scheme depicted in Fig. I. Parameter estimates and
coefficients of variation were generated based on mean data (n=8 healthy subjects) from a previously
published report (6).
Parameters Estimate CV (%)
Kabsorb (h−1) 1.67 23.0
Vc (L) 55.8 7.71
K12 (h−1) 0.124 11.0
K21 (h−1) 0.00788 49.7
Kbile (h−1) 0.0438 11.1
Kurine (h−1) 0.0689 10.1
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Table III





0.5 µM Fexofenadine +
2 µM GF120918
0.5 µM Fexofenadine +
5 µM Bosentan
Css,out (pmol/mL) # 92.3 ± 29.4 135 ± 21 172 ± 59* 209 ± 19*
Cliver (pmol/mL) 7295 ± 786 7156 ± 1529 8159 ± 720 5561 ± 873
Cliver, unbound (pmol/mL) 1389 ± 196 1282 ± 142 1631 ± 620 1235 ± 369
Cliver, unbound / Css,out 16.2 ± 5.4 9.53± 0.46 10.8 ± 6.0 6.05 ± 2.34*
Extraction Ratio 0.82 ± 0.06 0.73 ± 0.04 0.66 ± 0.12* 0.58± 0.04*
Biliary Excretion Rate
(pmol/min/g liver)
218 ± 66 136 ± 34* 55.6 ± 6.4* 142 ± 29
Cl’biliary (mL/h/g liver) 8.57 ± 2.00 6.56 ± 2.27 2.36 ± 1.12* 7.52 ± 2.78
*
p< 0.05 fexofenadine ± modulator vs. fexofenadine alone.
#
Total concentration determined based on 50–60-min collection interval. Perfusate buffer contained 5 µM taurocholate (TC), unless otherwise
noted.
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